FDA approves Atebrioz for rare disease that forms bone in soft tissues

The U.S. Food and Drug Administration approved Atebrioz, or zilurgisertib, on September 25 for adults and children aged 12 and older with fibrodysplasia ossificans progressiva, a rare genetic disorder in which bone forms in soft tissues. The decision adds a treatment option for a disease that progressively restricts movement and independence.

The approved indication is to reduce the volume of total new heterotopic ossification—the medical term for bone formation outside the skeleton. FDA describes Atebrioz as the third approved treatment for the condition. Its approval establishes a specific use in this disease; it does not establish an effect on ordinary skeletal aging or lifespan.

### What the trial measured

FDA based its effectiveness assessment on a randomized, double-blind, placebo-controlled trial involving 63 patients. During the 24-week comparison, participants received either zilurgisertib or placebo. Whole-body CT scans measured changes in abnormal bone volume.

At week 24, FDA reported an average decrease of 3.2 cubic centimeters in total new heterotopic ossification in the treatment group, compared with an increase of 24.6 cubic centimeters in the placebo group.

The companies’ announcement clarifies an important feature of that endpoint: total new lesion volume included both changes involving lesions present at baseline and newly developing discrete lesions. The negative average therefore should not be read as proof that the treatment eliminates established abnormal bone or reverses disability.

Mirum Pharmaceuticals and Incyte identify the trial as PROGRESS, a phase 2 study. Their announcement says the randomized cohort enrolled patients aged 12 and older and that treatment effects were maintained through week 48 during an open-label extension.

That later observation provides additional follow-up, but it has a different evidentiary status from the blinded comparison. Once participants receive active treatment without a concurrent placebo group, attributing subsequent changes specifically to the medicine becomes more difficult.

### A pathway tied to progressive disability

Zilurgisertib inhibits activin receptor-like kinase 2, or ALK2. According to the companies, disease-causing variants in the ACVR1 gene lead to abnormal activation of this pathway, contributing to bone formation in muscles, tendons, ligaments and other soft tissues.

The healthspan relevance is preservation of physical function in a lifelong disabling condition. However, measuring bone volume and demonstrating sustained improvements in daily activity are different tasks. The approval summaries establish an imaging-based treatment effect; they do not establish restored mobility or longer survival.

The study’s size and the 24-week controlled period also limit conclusions about uncommon adverse effects and the durability of benefit over many years. Those questions matter when treatment is intended for a progressive condition that can begin early in life.

### Safety and the next evidence questions

FDA warns that Atebrioz can cause fetal harm, based on animal studies, and identifies medication-interaction restrictions. Common adverse effects include headache, joint pain, upper respiratory tract infection, nosebleeds and nausea.

Incyte developed the medicine and licensed it to Mirum for worldwide development and commercialization. The companies said on September 25 that U.S. commercial availability was expected in October; that remains a stated launch expectation rather than evidence of availability on the approval date.

For clinicians and researchers, the next questions extend beyond the scan result: how reliably the effect persists, whether it translates into preserved independence, and how safety evolves with longer exposure. The new authorization expands treatment choice while leaving those longer-term outcomes to be established.